Navigation Links
6th ESOU Meeting
Date:12/16/2008

The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in Istanbul, Turkey, from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists.

With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologists, scientists and researchers the opportunity to explore the various options that will enable cancer specialists to identify optimal treatment approaches.

"The ESOU is and intends to remain - one of the most important platforms of scientific information exchange among experts as well as professionals interested in the field. It will continue to serve as a key opinion leader and promote the dissemination of high-quality uro-oncological scientific information, in order to increase the quality of medical service," said ESOU Chairman Prof. Vincent Ravery (Paris, France).

The most common malignancies such as prostate cancer (PCa), renal cell carcinoma and bladder cancer were the focus of last year's meeting in Berlin. Apart from these conditions, testis cancer will be another highlight of the forthcoming meeting in Istanbul.

Prof. Levent Trkeri (Istanbul, Turkey), ESOU board member and local organiser said: "On Friday, 16 January, an interesting pro-contra debate is organised entitled 'Should hormones (adjuvant/neo-adjuvant) be dedicated to radiotherapy and abandoned in patients to be treated with surgery?' Furthermore, the lecture by Prof. Theo de Reijke of the European Organisation on the Research and Treatment of Cancer-Genitourinary Group (Update on the recent data retrieved from EORTC GU group studies) deserves attention."

The introduction of targeted therapies, which will be discussed during the sessions on renal cell carcinoma, meant a revolution in the field of oncology in general. These therapies appear to evolve into the mainstay of medical
'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
31-263-890-680
European Association of Urology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Society for General Microbiology 161st Meeting, University of Edinburgh
2. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
3. Colony collapse disorder symposium added to ESA Annual Meeting
4. Meeting real-world climate information needs of business, government
5. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
6. NAS Biodiversity and Extinction Meeting Dec. 7-8
7. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
8. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
9. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
10. Media advisory -- 2008 Ocean Sciences Meeting
11. ASNTR 15th anniversary meeting to be held May 1-3 in Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Move over Longface, Spooktacular and Trickster - theres ... Bulldog, a new variety of the familiar fall fruit ... pumpkin growers. Researchers at the University of Georgia recently ... fall and Halloween displays. Dr. Gerard Krewer from ...
... release is available in French . , ... researchers has completed a massive survey of the network ... life. In the online edition of the journal Science, ... and networks of complexes never before observed including ...
... NY, May 13, 2008Gene therapy to replace the faulty CLN2 ... age 8-12 years, was able to slow significantly the rate ... published online ahead of print in the May 2008 issue ... journal published by Mary Ann Liebert, Inc. The paper is ...
Cached Biology News:Researchers discover architecture for fundamental processes of life 2Gene therapy slows progression of fatal neurodegenerative disease in children 2
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has priced an underwritten registered ... a price of $9.00 per share, and granted the ... up to an additional 585,000 shares of its common ... $35.1 million.  The offering is expected to close on May ...
(Date:5/1/2015)... May 1, 2015 A new ... antithrombotic drugs will reach $22.4bn in 2019. That revenue ... Industry and Market Prospects 2015-2025 ,  published ... investigation is to provide forecasts and qualitative analyses of ... publisher and consultancy in London, UK ...
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... DIEGO, April 27 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis and treatment of coronary and peripheral ... results for the first quarter of fiscal 2009 on Tuesday, ... its financial results and operating activities open to all interested ...
... Initial Cohort Shows Nine of 14 Evaluable Patients ... Achieved an Objective Tumor Response -- Patient Dosing ... of Enrolling 46 Patients Overall -TUSTIN, Calif., April ... PPHM ), today announced that updated preliminary data ...
... 27 Xspray Microparticles AB, the Swedish,life ... solution for,pharmaceutical particle production based on supercritical ... overcomes many of,the drawbacks of traditional micronization ... well as offering all the advantages of ...
Cached Biology Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 4Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 2Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 3
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Request Info...
Biology Products: